Spyre Therapeutics, Inc ((SYRE)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Spyre Therapeutics, Inc. is conducting a clinical study titled ‘A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-091 in Healthy Participants.’ The study aims to evaluate the safety and tolerability of SPY002-091, a new drug, in healthy volunteers, marking a significant step in its development pipeline.
The intervention being tested is SPY002-091, an experimental drug administered in a single ascending dose format to assess its safety and pharmacokinetics. A placebo is used for comparison.
This Phase 1 study is interventional with a randomized allocation and a sequential intervention model. It employs a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are blinded, with the primary purpose being basic science.
The study began on November 1, 2024, with the latest update submitted on August 13, 2025. These dates highlight the study’s current recruiting status and ongoing data collection.
The study’s progress could influence Spyre Therapeutics’ stock performance and investor sentiment, as successful results may enhance the company’s market position. Investors should also consider the competitive landscape, as other companies in the industry may be pursuing similar innovations.
The study is ongoing, with further details available on the ClinicalTrials portal.